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. Patient characteristics for the full cohort and stratified by change in statin adherence after AMI. Table S2 . Full model results for the association between all-cause mortality and post-AMI statin adherence, while adjusting for pre-AMI statin adherence. Table S3 . Full model results for the association between all-cause mortality and change in statin adherence after acute myocardial infarction (AMI). Table S4 . Crude estimates and models adjusted iteratively based on the timing of covariate measurement for the association between all-cause mortality and change in statin adherence after acute myocardial infarction (AMI). Table S5 . Sensitivity analyses involving changing variable definitions or adding new variables to the model estimating the association between all-cause mortality and change in statin adherence after acute myocardial infarction (AMI). Table S6 . Sensitivity analyses with restricted study eligibility estimating the association between all-cause mortality and change in statin adherence after acute myocardial infarction (AMI). Table S7 . Association between all-cause mortality and change in statin adherence, adjusted for changes in ACE/ARB and beta-blocker adherence, among the subgroup of prevalent users for all 3 medication classes: models adjusted iteratively based on the timing of covariate measurement and comparison to final model from manuscript. Table S8 . Full model results for the association between all-cause mortality and change in statin adherence after acute myocardial infarction, adjusted for changes in ACE/ARB and beta-blocker adherence, among the subgroup of prevalent users for all 3 medication classes (N=48,580). Figure S1 . Unadjusted survival curves and 95% confidence bands for all-cause mortality after acute myocardial infarction, stratified by statin adherence. Percentages are column percents. Statin adherence was measured separately in the 6 months pre-AMI and the 6 months post-AMI. Adherence was categorized as follows: severely nonadherent (PDC <40%), moderately nonadherent (PDC 40-79.9%), and adherent (PDC ≥80%). For absolute standardized difference calculations, all statin adherence change groups are compared to the group who was severely nonadherent both pre-and post-AMI. * Absolute standardized difference ≥10% compared to the reference group (severely nonadherent both pre-and post-AMI n (%) % % % % % % % % % ## Continuous weighted average of the simvastatin-equivalent average daily dose in the post-AMI period minus the weighted average in the pre-AMI period. Dose equivalency calculations were made as follows: fluvastatin, pravastatin, and lovastatin doses in mg were divided by 4, 2, and 2, respectively; atorvastatin, rosuvastatin, and pitavastatin doses were multiplied by 2, 4, and 10, respectively. *** At least one prescription fill within medication class during the index AMI hospitalization period or within 6 months after index AMI discharge date.
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† † † Inpatient ICD-9 diagnosis code of 410.x1 in the primary or secondary discharge field within 6 months after index AMI discharge date. ‡ ‡ ‡ Inpatient ICD-9 diagnosis code of 430, 431, 433.x1, 434.x1, or 436 in the primary discharge field within 6 months after index AMI discharge date. § § § According to the 2013 American College of Cardiology/ American Heart Association guidelines on the reduction of atherosclerotic cardiovascular risk.
∥∥∥ Intensity of the last statin prescription fill before the index AMI.
### Intensity of the first statin prescription fill after the index AMI.
**** Inpatient or outpatient ICD-9 diagnosis code of 272.xx in any position.
Abbreviations: ACE, angiotensin-converting enzyme; ADD, average daily dose; Adh, Adherent; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass surgery; CCI, Charlson comorbidity index; ICD-9, International Classification of Diseases, Ninth Revision; Mod NA, moderately nonadherent; PDC, proportion of days covered; PTCA, percutaneous transluminal coronary angioplasty; Sev NA, severely nonadherent; std, standard deviation. These are the results for the fully adjusted Cox proportional hazards model also presented in Figure 5 within the manuscript. The purpose of this model was to estimate the association between all-cause mortality and change in statin adherence. * Statin adherence was measured separately in the 6 months pre-AMI and the 6 months post-AMI. Adherence was categorized as follows: severely nonadherent (PDC <40%), moderately nonadherent (PDC 40-79.9%), and adherent (PDC ≥80%). Change in statin adherence was defined as a categorical change in statin adherence. † Enrolled in Medicare and Medicaid. ‡ Median household income of US Census block groups for individuals aged 65 and older. § Measured in the 12 months prior to the index AMI hospital admission date. ∥ CCI score does not include counts for AMI and dementia. # CCI definition. ** Medicare Chronic Conditions Data Warehouse definition. † † First prescription claim for a statin was identified during the 6 months prior to the index AMI hospital admission date. ‡ ‡ At least one prescription fill within medication class during the 6 months prior to the index AMI hospital admission date. § § Index AMI had diagnosis code for subendocardial infarction, compared to transmural infarction. ∥∥ Primary care physician, physician assistant, or nurse practitioner. ## Continuous weighted average of the simvastatin-equivalent average daily dose in the post-AMI period minus the weighted average in the pre-AMI period. Dose equivalency calculations were made as follows: fluvastatin, pravastatin, and lovastatin doses in mg were divided by 4, 2, and 2, respectively; atorvastatin, rosuvastatin, and pitavastatin doses were multiplied by 2, 4, and 10, respectively. *** At least one prescription fill within medication class during the index AMI hospitalization period or within 6 months after index AMI discharge date.
† † † Inpatient ICD-9 diagnosis code of 410.x1 in the primary or secondary discharge field within 6 months after index AMI discharge date. ‡ ‡ ‡ Inpatient ICD-9 diagnosis code of 430, 431, 433.x1, 434.x1, or 436 in the primary discharge field within 6 months after index AMI discharge date. § § § Inpatient or outpatient ICD-9 diagnosis code of 272.xx in any position.
Abbreviations: ACE, angiotensin-converting enzyme; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass surgery; CCI, Charlson comorbidity index; CI, confidence interval; HR, hazard ratio; ICD-9, International Classification of Diseases, Ninth Revision; PDC, proportion of days covered; PTCA, percutaneous transluminal coronary angioplasty. Cox proportional hazards models. The first model on the left ("Crude estimates") is unadjusted for other covariates. Each model is then adjusted for an additional set of covariates based on when the variables were measured (sociodemographics, pre-AMI comorbidities/medications, characteristics of the index AMI hospitalization, and post-AMI follow-up/medications/stroke/recurrent AMI). * Point estimate does not fall within the 95% confidence interval for the fully adjusted model. † Fully adjusted model also presented in Figure 5 within the manuscript. Abbreviations: AMI, acute myocardial infarction; CI, confidence interval; Hosp, measures from the index AMI hospitalization; HR, hazard ratio; Pre, pre-AMI measures; Sociodem, sociodemographic measures.
